UCSF home page About UCSF UCSF Medical Center
UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Decrease the text sizeRestore original text sizeIncrease the text size Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.
Transporter Database banner  
Decrease the text size | Restore text size | Increase the text size
 Text Sizer image
Home About and More Information Transporter Data Index
Search:  
 

SLC22A7

Synonyms: MGC24091, MGC45202, NLT, OAT2

Entrez Gene Link

Expression Data
Substrate Information
Inhibitor Information
Clinical Drug-drug Interactions

Expression Data

Expression data for other tissues could be found in http://pharmacogenetics.ucsf.edu/gtex/index.html

Asterisk indicates important transporters in the organ as identified in the organ diagram.

Organ Source Relative Expression
Brain Nishimura    0.000555
Kidney* Nishimura    0.471
Liver* Nishimura    0.818
Placenta Nishimura    0.0000503
Small Intestine Nishimura    0.000686
Kidney* Mean across all PMT Samples 14.003
Liver* Mean across all PMT Samples 128.423
Note that relative expression values should only be compared between entries of the same source.

Back to top

In Vitro Substrates

Substrate Km (μM) Cell System Reference
2'-deoxyguanosine 128 HEK-OAT2 Cropp, 2008
5-fluorouracil 0.0538 OAT2-expressing oocytes Kobayashi, 2005
Bumetanide 7.52 OAT2-expressing oocytes Kobayashi, 2005
Cyclic GMP 88 HEK-OAT2 Cropp, 2008
Erythromycin 18.5 OAT2-expressing oocytes Kobayashi, 2005
Paclitaxel 0.1428 OAT2-expressing oocytes Kobayashi, 2005
Prostaglandin E2 0.713 S2-OAT2 Kimura, 2002
Prostaglandin F2-alpha 0.425 S2-OAT2 Enomoto, 2002
Tetracycline 439.9 S2-OAT2 Babu, 2002
Theophylline 12.6 OAT2-expressing oocytes Kobayashi, 2005
Zidovudine 26.8 S2-OAT2 Takeda, 2002

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

In Vitro Inhibitors

Inhibitor IC50 (μM) Ki (μM) Substrate used Cell System Reference
(-)-Zearalenone 149 Prostaglandin F2-alpha S2 cells Tachampa, 2008
Aflatoxin B1 1502 Prostaglandin F2-alpha S2 cells Tachampa, 2008
Alpha-zearalenol 180 Prostaglandin F2-alpha S2 cells Tachampa, 2008
Bumetanide 77.5 Prostaglandin F2-alpha S2-OAT2 Hasannejad, 2004
Cefamandole 1570 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2003
Cefoperazone 1330 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2003
Cefotaxime 4680 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2003
Cephaloridine 4480 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2003
Cephalothin 1410 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2003
Chlorothiazide 2205 Prostaglandin F2-alpha S2-OAT2 Hasannejad, 2004
Cyclic GMP 93 2'-deoxyguanosine HEK-OAT2 Cropp, 2008
Cyclopiazonic acid 126 Prostaglandin F2-alpha S2 cells Tachampa, 2008
Cyclothiazide 39.2 Prostaglandin F2-alpha S2-OAT2 Hasannejad, 2004
Diclofenac 14.3 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2002
Ethacrynic acid 121 Prostaglandin F2-alpha S2-OAT2 Hasannejad, 2004
Furosemide 603 Prostaglandin F2-alpha S2-OAT2 Hasannejad, 2004
Hydrochlorothiazide 1023 Prostaglandin F2-alpha S2-OAT2 Hasannejad, 2004
Ibuprofen 692 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2002
Indomethacin 64.1 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2002
Ketoprofen 400 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2002
Mefenamic acid 21.7 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2002
Naproxen 486 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2002
Phenacetin 1878 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2002
Piroxicam 70.3 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2002
Probenecid 766 Prostaglandin F2-alpha S2-OAT2 Enomoto, 2002
Sulindac 440 Prostaglandin F2-alpha S2-OAT2 Khamdang, 2002
Trichlormethiazide 1120 Prostaglandin F2-alpha S2-OAT2 Hasannejad, 2004

ND = not determined
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Clinical Drug-Drug Interactions

DDI Implicated Transporter Interacting Drug Affected Drug AUC Cmax CLR CL/F t1/2 Effect on PD Reference More Details
Clinical PK Impact(fold change)
1 OATs/OCTs Cotrimoxazole (trimethoprim/sulfamethoxazole) Apricitabine 1.7 1.3 0.6 0.6 1.4 ND Shiveley, 2008 DDI 1
2 OATs/OCTs Cotrimoxazole (trimethoprim/sulfamethoxazole) Zidovudine NS ND 0.4 NS NS ND Chatton, 1992 DDI 2
3 OATs Furosemide Lomefloxacin 1.1 NS 0.7 0.9 NS ND Sudoh, 1994 DDI 3
4 OATs Probenecid Acyclovir 1.4 ND 0.7 NS ND ND Laskin, 1982 DDI 4
5 OATs Probenecid Cefaclor 2.1 1.5 ND ND 1.6 ND Welling, 1979 DDI 5
6 OATs Probenecid Cefonicid 2.1 1.2 0.3 ND 1.5 ND Pitkin, 1981 DDI 6
7 OATs Probenecid Cefoxitin 2.4 ND 0.4 ND 2.0 ND Vlasses, 1980 DDI 7
8 OATs Probenecid Ceftriaxone 0.7 ND ND 1.3 0.8 ND Stoeckel, 1988 DDI 8
9 OATs Probenecid Cephradine 2.4 1.9 ND ND 1.5 ND Welling, 1979 DDI 9
10 OATs Probenecid Cidofovir ND ND 0.5 0.6 ND ND Cundy, 1995 DDI 10
11 OATs/MRPs Probenecid Ciprofloxacin 1.7 NS 0.4 0.6 1.5 ND Jaehde, 1995 DDI 11
12 OATs Probenecid Dicloxacillin 1.9 1.8 0.3 0.5 ND ND Beringer, 2008 DDI 12
13 OATs Probenecid Famotidine 1.8 1.5 0.4 0.1 NS ND Inotsume, 1990 DDI 13
14 OATs/MRPs Probenecid Furosemide 2.7 1.5 0.3 0.4 1.7 ND Vree, 1995 DDI 14

The transporters are implicated by in vitro data and/or studies in humans with genetic polymorphisms of the transporter
DDI = Drug Drug Interaction
PK = pharmacokinetic
PD = pharmacodynamic
ND = not determined
NS = not significant
N/A = information not available
Calculation of Fold Change: fold change in the presence of the interacting drug = (value with interacting drug)/(value without interacting drug)
fold change > 1: increase in pharmacokinetic value
fold change < 1: decrease in pharmacokinetic value
1 denotes drugs that can potentially be used as in vitro substrates for studies of the transporter as defined by the FDA as of March 2022
2 denotes drugs that can potentially be used as in vitro inhibitors for studies of the transporter as defined by the FDA as of March 2022
3 denotes drugs that can potentially be used as clinical substrates for studies of the transporter as defined by the FDA as of March 2022
4 denotes drugs that can potentially be used as clinical inhibitors for studies of the transporter as defined by the FDA as of March 2022


Back to top

Contact us | Glossary

Blue banner